TWI237637B - 5-trityloxymethyl-oxazolidinones and process for the preparation thereof - Google Patents
5-trityloxymethyl-oxazolidinones and process for the preparation thereof Download PDFInfo
- Publication number
- TWI237637B TWI237637B TW090122961A TW90122961A TWI237637B TW I237637 B TWI237637 B TW I237637B TW 090122961 A TW090122961 A TW 090122961A TW 90122961 A TW90122961 A TW 90122961A TW I237637 B TWI237637 B TW I237637B
- Authority
- TW
- Taiwan
- Prior art keywords
- scope
- patent application
- item
- organic solvent
- trityl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 25
- NONOANCJDOAYFL-UHFFFAOYSA-N 5-(trityloxymethyl)-1,3-oxazolidin-2-one Chemical class O1C(=O)NCC1COC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 NONOANCJDOAYFL-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 8
- 239000003960 organic solvent Substances 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 8
- -1 alkaline earth metal hypochlorite Chemical class 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims 3
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Chemical group Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 claims 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
- ARZSRJNMSIMAKS-UHFFFAOYSA-N 4-aminobutane-1,2-diol Chemical compound NCCC(O)CO ARZSRJNMSIMAKS-UHFFFAOYSA-N 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- XXFXTBNFFMQVKJ-UHFFFAOYSA-N [diphenyl(trityloxy)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXFXTBNFFMQVKJ-UHFFFAOYSA-N 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- 235000013339 cereals Nutrition 0.000 claims 1
- 239000002274 desiccant Substances 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 150000004692 metal hydroxides Chemical class 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 abstract description 3
- 239000004599 antimicrobial Substances 0.000 abstract description 3
- 230000003542 behavioural effect Effects 0.000 abstract description 3
- TWONBQKNUBYLDQ-UHFFFAOYSA-N 3-hydroxy-4-trityloxybutanamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(O)CC(=O)N)C1=CC=CC=C1 TWONBQKNUBYLDQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001412 amines Chemical group 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000002079 cooperative effect Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical group NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical compound CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- COPNBMBEZMJJPT-UHFFFAOYSA-N 3,4-dichlorobutan-1-ol Chemical compound OCCC(Cl)CCl COPNBMBEZMJJPT-UHFFFAOYSA-N 0.000 description 1
- DZAIOXUZHHTJKN-UHFFFAOYSA-N 3,4-dihydroxybutyric acid Chemical compound OCC(O)CC(O)=O DZAIOXUZHHTJKN-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100020870 La-related protein 6 Human genes 0.000 description 1
- 108050008265 La-related protein 6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical group 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- JDRMYOQETPMYQX-UHFFFAOYSA-N monomethyl succinate Chemical class COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 description 1
- JJYKJUXBWFATTE-UHFFFAOYSA-N mosher's acid Chemical compound COC(C(O)=O)(C(F)(F)F)C1=CC=CC=C1 JJYKJUXBWFATTE-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BXEMXLDMNMKWPV-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1 BXEMXLDMNMKWPV-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007070 tosylation reaction Methods 0.000 description 1
- 238000005866 tritylation reaction Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
1237637 A7 五、發明説明(01 名稱:5_二苯甲氧甲基4錢_及其製備方法 摘要: —本發明描述-種於單—步財直接自旋光性3遍基冬 二笨甲氧基丁醯胺製備經保護、較佳為對掌性之S三苯甲 虱甲基气吐㈣的方法。σ号口坐咬嗣係為醫藥工業中的一種 重要分子,尤其是在抗微生物劑及行為障礙之領 詳細說明: < ΜΜ相關申諸者朱1 無 展之陵沭 -—0^-- (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 無 發明背景 ⑴發明領坺 本發明有關-種自3-絲·4·三苯^氧基丁醯胺製得5-二苯甲氧甲基噚唑啶酮之單階路徑。本發明尤其有關5_三 苯甲氧甲基谔唑啶酮之對掌性形式的製備。(2) iKMMMAJL 具有光學純度之哼唑啶酮可藉著使用試劑諸如光氣、 氯甲酸乙酯及羰基咪唑使連位胺基醇進行羰基化而製得。 具有光學純度之5·三苯甲氧甲基哼唑啶酮之製備一般需要 製備對應之具有光學純度的5-經甲基哼吐啶酮,之後進行 三苯甲基化步驟,以製得5-三苯甲氧甲基σ号唑啶酮。 °亏峻哫酮類在藥物發展上顯然係極重要的一類化合 物’尤其是抗微生物劑領域中(〇4]^11^,〇.了.等人,〇1'1^59 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 訂 4. 1237637 A7 B7 五、發明説明(02 ) (請先閲讀背面之注意事項再填寫本頁) 7-16 (2000))及行為障礙(Brenner,R等人,cnn 丁以以^如22 4 411-419 (20_。尤其具有對抗部分最具抗藥性之人類病 原的活性,包括抗萬古黴素腸球菌、抗甲氧苯青黴素金黃 色葡萄球菌、抗頭孢菌素肺炎鏈球菌及數種顯示抗青徽素 性貝之有機物(Diekema’ D· J.等人,j)rugs 59 7-16 (2000))。 林若利(LineZ〇id)(4)係最近建議用以治療抗生素抗藥性菌株 之感染的藥物,尤其是抗萬古黴素者。1237637 A7 V. Description of the invention (01 Name: 5_Dibenzomethylmethyl 4-money_ and its preparation method Abstract:-Description of the invention-Kind of single-Bucai direct spin optical properties of 3 times Jidong Dibenjia Method for the preparation of protected but preferably palmitic S-tribenzyl methacetate by oxybutyramine. The sigma-stomach σ is an important molecule in the pharmaceutical industry, especially in antimicrobials Agents and Behavioral Disorders Details: < MM Related Applicant Zhu 1 Tomb of Wuzhan --- 0 ^-(Please read the precautions on the back before filling out this page) Staff Consumer Cooperatives, Central Standards Bureau, Ministry of Economic Affairs Printed without background of invention (Invention collar) The present invention relates to a single-stage path for preparing 5-dibenzyloxymethyloxazolidinone from 3-sil · 4 · triphenyl ^ butoxymidine. This invention It is particularly relevant to the preparation of the palmitate form of 5-tribenzyloxymethyloxazolidinone. (2) iKMMMAJL The oxazolidinone with optical purity can be obtained by using reagents such as phosgene, ethyl chloroformate and carbonylimidazole It is prepared by carbonylating a vicinal amine alcohol. Preparation of 5. · tribenzyloxymethyl oxazolidone with optical purity In general, it is necessary to prepare the corresponding 5-transmethyl humidone with optical purity, and then perform a tritylation step to obtain 5-tribenzyloxymethyl sigmazodone. ° 哫 峻 哫Ketones are obviously a very important class of compounds in drug development, especially in the field of antimicrobial agents (〇4] ^ 11 ^ , 〇. 了. Et al., 〇1'1 ^ 59 This paper standard applies to Chinese national standards ( CNS) A4 specification (210X297 mm) Order 4. 1237637 A7 B7 V. Description of the invention (02) (Please read the notes on the back before filling this page) 7-16 (2000)) and behavioral disorders (Brenner, R, etc. Human, cnn Ding Yi ^ such as 22 4 411-419 (20_. Especially has activity against some of the most resistant human pathogens, including vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, anti-cephalosporin Streptococcus pneumoniae and several organisms that show resistance to cyanogenin (Diekema 'D. J. et al., J) rugs 59 7-16 (2000)). LineZoid (4) is a recent recommendation Drugs used to treat infections with antibiotic-resistant strains, especially those resistant to vancomycin.
旋光性3,4-二羥基丁酸及其r-内酯係為對掌性之重要 來源。其可於工業量下藉著氧化降解而得自醣類諸如澱粉、 乳糖、麥芽糖糊精、纖維素及阿拉伯糖(Hollingsworth,R.I. Biotechnology Annual Review 2 281-291 (1996); 經濟部中央標準局員工消費合作社印製Optically active 3,4-dihydroxybutyric acid and its r-lactone are important sources of palmity. It can be obtained from sugars such as starch, lactose, maltodextrin, cellulose and arabinose by oxidative degradation in industrial quantities (Hollingsworth, RI Biotechnology Annual Review 2 281-291 (1996); employees of the Central Standards Bureau of the Ministry of Economic Affairs Printed by Consumer Cooperatives
Hollingsworth,R.I.,J. Org. Chem. 64 7633-7634 (1999))。亦 參照 Hollingsworth 之美國專利第 5,292,939 號、第 5,080,107 號、第5,319,110號及第5,374,773號。對掌性胺基丙烷二 醇可藉著旋光性3,4-二羥基丁酸醯胺之亞異丙基縮醛的霍 夫曼(Hoffman)降解而製得(Wang,G.等人,J· Org. Chem· 64 1036-1038 (1999))。 發明概述 本發明有關一種製備5-三苯甲氧甲基谔唑啶酮之方 法,其包括: 5 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) !237637 Μ 經濟部中央標準局員工消費合作社印製 五、發明説明(〇3 ) (a) 於驗金屬或鹼土金屬氫氧化物及有機溶劑存在下, 知反應奶合物中之3,4-二幾基丁酿胺的4-三苯甲基與驗 金屬或驗土金屬次卣酸鹽攪拌於水中以進行反應,而製得 5 -三苯甲氧甲基4 π坐咬酮; (b) 自有機落劑中之反應混合物分離該5-三苯甲氧甲基 。号唑啶酮;及 (c) 移除忒有機溶劑,以製得該5_三苯甲氧甲基呤唆啶 酉同。 本發明亦有關藉該方法製的之新穎5_三苯甲氧甲基。号 唑啶酮1。該化合物以對掌性為佳。 發明目的 因此,本發明之目的係提出一種可自酿胺之三苯甲基 _產製新穎4 5·三苯甲氧甲基酮的單階方法。此外, 本發明之一目的係提出對掌性產物之製備。此外,本發明 《目的係提出一種較先前技藝簡易且經濟之方法,於高 率及純度下產製該產物。參考以下y、+、 ° >亏以下描逑可更加明瞭此 其他目的。 較佳具體實例描沭 本發明方法所涉及之反應係如以下危 1况乜圖1所示。 Η 一 ΟΗ 〇 2 ΟΟΓ/ΟΗΓ •- νη2Hollingsworth, R.I., J. Org. Chem. 64 7633-7634 (1999)). See also U.S. Patent Nos. 5,292,939, 5,080,107, 5,319,110, and 5,374,773 of Hollingsworth. Palmitic aminopropanediol can be prepared by Hoffman degradation of isopropylidene acetal of optically active 3,4-dihydroxybutyric acid amine (Wang, G. et al., J Org. Chem. 64 1036-1038 (1999)). SUMMARY OF THE INVENTION The present invention relates to a method for preparing 5-tribenzyloxymethyloxazolidone, which includes: 5 paper sizes applicable to Chinese National Standard (CNS) A4 (210 X 297 mm)! 237637 Μ Ministry of Economic Affairs Printed by the Consumer Standards Cooperative of the Central Bureau of Standards V. Description of the Invention (〇3) (a) In the presence of metal or alkaline earth metal hydroxides and organic solvents, it is known that 3,4-dichlorobutanol in the reaction milk compound 4-tritylamine of amine and metal or earth metal hyporhenate are stirred in water for reaction to obtain 5-trityloxymethyl 4 π sitting bite ketone; (b) from organic solvents The reaction mixture in was isolated from the 5-trityloxymethyl group. Nozolidinone; and (c) removing the hydrazone organic solvent to obtain the 5-tribenzylmethoxine pyridine pyridine. The invention also relates to a novel 5-trityloxymethyl group made by this method. No. azolidinone 1. The compound is preferably palmar. OBJECTS OF THE INVENTION Therefore, the object of the present invention is to propose a single-stage method for producing novel 4 5 · trityloxymethyl ketones from a trityl group that can be brewed from amines. In addition, one object of the present invention is to propose the preparation of palm products. In addition, the purpose of the present invention is to propose a simpler and more economical method than the previous technique to produce the product at a high rate and purity. Refer to the following y, +, ° > descriptions below to make this other purpose more clear. The description of the preferred embodiment is as follows: The reaction involved in the method of the present invention is shown in Figure 1 below. Η 一 ΟΗ 〇 2 ΟΟΓ / ΟΗΓ •-νη2
Scheme 6 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐 ------噥------1T-----d (請先閱讀背面之注意事項再填寫本頁)Scheme 6 This paper size applies to China National Standard (CNS) A4 specifications (210X297 mm ------ 哝 ------ 1T ----- d (Please read the precautions on the back before filling this page )
I 經濟部中央標準局員工消費合作社印製 二個步驟係於以下條件下進行三苯甲基嶋之重上yI Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs
本紙張尺度適 (210x297公釐) 1237637 五、發明説明(05 ) 該胺驗以吼读為佳,唯可使用其他胺類諸如三乙胺,以血 該反應中所產製之HCI或其他酸進行反應。該有機溶劑以、 二甲基甲醯胺與四氫吱喃之混合物為佳,不含水。該溶叫 較佳㈣真f移除,之後使用己垸洗條乙醚,以移除過i 4二麥T基ϋ。該溫度係介於約5。& 4Q<t之間,而壓力 係為 大氣壓。該反應係於24至48小時内完成。隨後使用此三 麥甲基酸以形成該°号口坐途g同。 因此,本發明提出一種經三苯甲基保護、具 度之5-經甲基+坐咬酉同諸如⑻_5-三苯甲氧基甲基4㈣ 酉同⑴’其係在簡易之高產率方法中’使用對掌性3,心二經 基I祕《4-0-三苯甲基_為起始物質,而自旋光性弘 嫂基-r-丁内酯製得。 ^為^水進行水解之異氰酸㈣為霍夫曼(祕 =中(中間物質’基本上連位經基可作為導致環化之親 形成酮系統。於本發明中,避免使用光氣、 =:?:分個別羰基化反應。此係說 基丁酸_(狀4:=酸仙一二- 包括开% 序基本上僅包括兩個步驟,其中僅有一個 己# ^ 1。第—步驟係、自二經基丁 S!胺2---種 氨水溶液處理3-Λ二二基此驢胺係於室溫下使用 t巷-7 -丁内酯而於定量 I 1T (請先閲讀背面之注意事項再填寫本f) 1237637 A7 五、發明説明(06 中間體異氰酸酿⑶係經保護以隔離水,使得相鄰之幾基參 與’同時保護最終產物以防止驗水解。使用2相溶劑系統_ -此情況下為四氫吱喃/水—之霍夫曼重排直接產生細保確 之幾甲基十坐咬丄,單離產率>9〇卩分比,而光學純度>9又9 百分比。此情況表示於基本上4步驟中自殿粉、麥芽糖、 «或類似4_經鍵結醣來源合成重要、具光學純度、㈣ 狀5-(禮甲基峻相的極重要經濟性。該三苯甲基 可選擇性地移除,使得該H甲基官能性轉變成各式久樣之 取代基。該環氮亦可藉著置換氫而經垸基化或驢化^兩 特徵使其可輕易得到極大·之可能藥物候選物。 實施例 訂 /下係為製備經保護5_三苯甲氧基甲基_嘮唑啶酮之步 濟 部 中 央 準 員 工 消 f 合 作 社 印 3-羥基三苯甲氧基丁醯胺⑺之製備Μ”克莫 耳)(S)-3,4-二經基-丁酸胺溶解於5〇毫升四氫咬喃及% = =二甲基甲醯胺中,添加1G毫升_基,之後為·克(〇二 莫耳)三苯甲基氯於燒瓶中。使用充填有氯化鈣之乾燥管以 排除濕氣。該反應混合物於室溫下攪掉36小時。此周期乂 後,過濾以移除固體。該液體於減壓下濃縮,以移除大= 分溶劑。該溶液倒入冰水中,攪拌半小時,自經三笨# 保護之醯胺移除水層。所得之半結晶狀液體產物於=基 乾燥。使用己烷濕磨以洗除過量之三苯甲基氯。產量^下 33.0克(91百分比)。物理數據:熔點59|6〇〇它(得=== 二氯甲烷:己烷:丙酮= 6:3:〇·5)〔 α〕'Mb。(二^劑 本紙張尺關家鮮(c叫公I y 1237637 A7 B7 五、發明説明(08 ) (Mosher’s acid))衍生物之GC分析,產物之光學純度>99.9 e.i 熟習此技藝者可依習用方式將該5-三苯甲氧基甲基-呤唑啶 酮脫保護(例如氫解或HBr處理),而用以製備重要之5-乙 醯胺甲基呤唑啶酮(如各個專利所述,例如Pearlman等人 之美國專利第5,837,870號)。該羥基可藉任何已知方法轉 化成含氮之官能基。此等方法係包括甲磺醯化或甲苯磺醯 化,之後使用氨、疊氮化物、苄基胺及其他氮親核劑置換, 如以下流程圖2所示。 人 .MesylcWoride 9 」 十 ^ R Pyridke- 1 R 1 ίί" or-H2The size of this paper is suitable (210x297 mm) 1237637 V. Description of the invention (05) The amine test is better to read out. Only other amines such as triethylamine can be used to produce HCI or other acids produced in this reaction. Perform the reaction. The organic solvent is preferably a mixture of dimethylformamide and tetrahydrofuran, and does not contain water. The solvent is preferably removed, and then washed with diethyl ether to remove i 4 dimethyl T-based hydrazone. This temperature is between about 5. & 4Q < t, and the pressure is atmospheric. The reaction was completed in 24 to 48 hours. This triglycinic acid is subsequently used to form the mouthpiece g. Therefore, the present invention proposes a triphenylmethyl-protected, 5-methyl group + seat bite with a degree such as ⑻_5-tritylmethoxymethyl 4 酉 酉 with ⑴ ', which is in a simple and high yield method 'Using palmarity 3, the cardinal dimer radical I, "4-0-trityl-" as the starting material, and spin optically sulfonyl-r-butyrolactone. ^ Isocyanate hydrolyzed by water is Huffman (secret = medium (intermediate substance 'basically connected via a radical can be used as a cyclization to form a ketone system. In the present invention, the use of phosgene, =:?: Divided into individual carbonylation reactions. This is said that butyric acid _ (like 4: = acid succinic acid-including open %% sequence basically consists of only two steps, of which only one has ## 1. 第 — Steps are based on the treatment of 2-butyridine S! Amine 2 --- ammonia solution in aqueous 3-Λdidiyl. This donkey amine is used at room temperature to quantify I 1T (please first Read the notes on the back and fill in this f) 1237637 A7 V. Invention description (06 Intermediate isocyanate is protected to isolate water, so that adjacent groups participate in 'while protecting the final product to prevent hydrolysis. Use 2-Phase Solvent System _-In this case, Tetrahydrocondensate / water-the Huffman rearrangement directly produces a few fidelity methyl succinates, with an isolated yield of> 90%, and Optical purity> 9 and 9 percentages. This condition indicates that in 4 basic steps, the synthesis from the powder, maltose, «or similar 4_ bond sugar source is important, bright Purity, 5--like 5- (methyl ether phase is very important economical. The trityl group can be selectively removed, so that the H methyl functionality is transformed into a variety of substituents. The ring nitrogen It can also be replaced by hydrogen to be fluorinated or donated. The two characteristics make it easy to obtain a possible drug candidate with great potential. The example / underline is to prepare a protected 5-triphenylmethoxymethyl group. Oxidazolidone Preparation by the Central Associate of the Ministry of Economic Affairs, Cooperative Society, Preparation of 3-Hydroxytriphenoxybutyridamine, ”" Mkol ", (S) -3,4-Dimethyl-butyric acid amine Dissolved in 50 ml of tetrahydrofuran and% == dimethylformamide, add 1G ml_ group, and then · g (0 mol) of trityl chloride in the flask. Use filled with chlorine Dry the tube of calcium to remove moisture. The reaction mixture was stirred off at room temperature for 36 hours. After this period of time, it was filtered to remove solids. The liquid was concentrated under reduced pressure to remove large solvents. The solution was poured into ice water and stirred for half an hour, and the aqueous layer was removed from the stilbamine protected by Sanben #. The obtained semi-crystalline liquid product was dried on a base. Wet mill to wash away excess trityl chloride. Yield: 33.0 g (91%). Physical data: melting point 59 | 600 (it is === dichloromethane: hexane: acetone = 6: 3: 〇 · 5) [α] 'Mb. (Two copies of this paper ruler Guan Jiaxian (c is called public y 1237637 A7 B7 V. Description of the invention (08) (Mosher's acid)) GC analysis of the derivative, the product Optical purity> 99.9 ei Those who are familiar with this technique can deprotect the 5-triphenoxymethyl-pyrazolidone (such as hydrogenolysis or HBr treatment) according to customary methods, and use it to prepare important 5- Acetaminophenmethylpyrazolidone (as described in various patents, such as US Patent No. 5,837,870 to Pearlman et al.). The hydroxyl group can be converted into a nitrogen-containing functional group by any known method. These methods include mesylation or tosylation, followed by substitution with ammonia, azide, benzylamine, and other nitrogen nucleophiles, as shown in Scheme 2 below. People .MesylcWoride 9 '' Ten ^ R Pyridke- 1 R 1 ίί " or-H2
〇A〇A
R I------I-丨~#-I (請先閲讀背面之注意事項再填寫本頁)R I ------ I- 丨 ~ # -I (Please read the notes on the back before filling this page)
MsOMsO
〇 NT HO、〇 NT HO,
Ο N ‘ TrOΟ N ‘TrO
0)N3. (b) H2 / catalyst (c) Ac200) N3. (B) H2 / catalyst (c) Ac20
00A 〇 NH00A 〇 NH
* · *聿 RX plu^ catalyst (X = halogen) H0 〇H* · * 聿 RX plu ^ catalyst (X = halogen) H0 〇H
、1T, 1T
又 〇 N AcHN〇 N AcHN
ΟΕΓ _· 經濟部智慧財產局員工消費合作社印製ΟΕΓ _ · Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs
OK HO NH2OK HO NH2
叉 〇 NH HOFork 〇 NH HO
HO NH2 HOHO NH2 HO
Scheme 2Scheme 2
TrO. 前文描述僅用以說明本發明,而本發明僅受限於以下 申請專利範圍。 11 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐)TrO. The foregoing description is only used to illustrate the present invention, and the present invention is limited only by the scope of the following patent applications. 11 This paper size applies to China National Standard (CNS) Α4 specification (210X297 mm)
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/665,508 US6288239B1 (en) | 2000-09-19 | 2000-09-19 | 5-trityloxymethyl-oxazolidinones and process for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI237637B true TWI237637B (en) | 2005-08-11 |
Family
ID=24670388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW090122961A TWI237637B (en) | 2000-09-19 | 2001-09-19 | 5-trityloxymethyl-oxazolidinones and process for the preparation thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6288239B1 (en) |
| EP (1) | EP1324989B1 (en) |
| JP (1) | JP3974035B2 (en) |
| KR (1) | KR100525882B1 (en) |
| AT (1) | ATE329910T1 (en) |
| AU (2) | AU7593701A (en) |
| CA (1) | CA2418200C (en) |
| DE (1) | DE60120729D1 (en) |
| TW (1) | TWI237637B (en) |
| WO (1) | WO2002024670A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU773218B2 (en) * | 1999-10-08 | 2004-05-20 | Debiopharm International Sa | Fab I inhibitors |
| EP1560584B1 (en) * | 2001-04-06 | 2009-01-14 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| AU2002367959A1 (en) * | 2001-10-18 | 2003-12-31 | Michigan State University | Process for the preparation of oxazolidinones and method of use thereof |
| ES2518316T3 (en) * | 2002-12-06 | 2014-11-05 | Debiopharm International Sa | Heterocyclic compounds, their manufacturing methods and their use in therapy |
| ATE409485T1 (en) * | 2003-03-17 | 2008-10-15 | Affinium Pharm Inc | PHARMACEUTICAL COMPOSITIONS CONTAINING FAB I INHIBITORS AND OTHER ANTIBIOTICS |
| US8450307B2 (en) * | 2004-06-04 | 2013-05-28 | Affinium Pharmaceuticals, Inc. | Therapeutic agents, and methods of making and using the same |
| US20090156578A1 (en) * | 2005-12-05 | 2009-06-18 | PAULS Henry | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents |
| WO2008009122A1 (en) * | 2006-07-20 | 2008-01-24 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab i inhibitors |
| EP3255045A1 (en) | 2007-02-16 | 2017-12-13 | Debiopharm International SA | Salts, prodrugs and polymorphs of fab i inhibitors |
| KR200453944Y1 (en) * | 2011-03-08 | 2011-06-03 | 조명호 | Food delivery container |
| SMT201900411T1 (en) | 2012-06-19 | 2019-09-09 | Debiopharm Int Sa | Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide |
| SMT202000719T1 (en) | 2016-02-26 | 2021-03-15 | Debiopharm Int Sa | Medicament for treatment of diabetic foot infections |
| HUE062061T2 (en) | 2019-02-14 | 2023-09-28 | Debiopharm Int Sa | Afabicin formulation, method for making the same |
| UA129222C2 (en) | 2019-06-14 | 2025-02-12 | Дебіофарм Інтернешнл С.А. | Afabicin for use for treating bacterial infections involving biofilm |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5122601A (en) * | 1990-12-07 | 1992-06-16 | Hawaiian Sugar Planters'association | Synthesis of 2,3,3',4,4'-penta-o-methylsucrose |
| CA2049536C (en) | 1991-05-13 | 1999-07-06 | Rawle I. Hollingsworth | Process for the preparation of 3,4-dihydroxybutanoic acid and salts thereof |
| CZ298060B6 (en) | 1996-04-11 | 2007-06-06 | Pharmacia & Upjohn Company | Process for preparing oxazolidinones |
| US5808107A (en) | 1997-10-31 | 1998-09-15 | Board Of Trustees Operating Michigan State University | Process for the preparation of hydroxy substituted gamma butyrolactones |
| IT1301977B1 (en) * | 1998-07-31 | 2000-07-20 | Sigma Tau Ind Farmaceuti | PROCEDURE FOR THE PREPARATION OF R - (-) - CARNITINA |
-
2000
- 2000-09-19 US US09/665,508 patent/US6288239B1/en not_active Expired - Fee Related
-
2001
- 2001-07-16 AU AU7593701A patent/AU7593701A/en active Pending
- 2001-07-16 EP EP01953494A patent/EP1324989B1/en not_active Expired - Lifetime
- 2001-07-16 KR KR10-2003-7002770A patent/KR100525882B1/en not_active Expired - Fee Related
- 2001-07-16 WO PCT/US2001/022296 patent/WO2002024670A1/en not_active Ceased
- 2001-07-16 AT AT01953494T patent/ATE329910T1/en not_active IP Right Cessation
- 2001-07-16 JP JP2002529080A patent/JP3974035B2/en not_active Expired - Fee Related
- 2001-07-16 CA CA002418200A patent/CA2418200C/en not_active Expired - Fee Related
- 2001-07-16 AU AU2001275937A patent/AU2001275937B2/en not_active Ceased
- 2001-07-16 DE DE60120729T patent/DE60120729D1/en not_active Expired - Fee Related
- 2001-09-19 TW TW090122961A patent/TWI237637B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE329910T1 (en) | 2006-07-15 |
| JP3974035B2 (en) | 2007-09-12 |
| EP1324989B1 (en) | 2006-06-14 |
| AU7593701A (en) | 2002-04-02 |
| CA2418200A1 (en) | 2002-03-28 |
| DE60120729D1 (en) | 2006-07-27 |
| CA2418200C (en) | 2006-07-04 |
| JP2004523473A (en) | 2004-08-05 |
| WO2002024670A1 (en) | 2002-03-28 |
| EP1324989A1 (en) | 2003-07-09 |
| EP1324989A4 (en) | 2005-07-20 |
| KR100525882B1 (en) | 2005-11-02 |
| KR20030025301A (en) | 2003-03-28 |
| AU2001275937B2 (en) | 2005-08-11 |
| US6288239B1 (en) | 2001-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI237637B (en) | 5-trityloxymethyl-oxazolidinones and process for the preparation thereof | |
| JP4278511B2 (en) | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | |
| TW204336B (en) | ||
| HU225810B1 (en) | Therapeutically effective tropane derivatives, process for their preparation pharmaceutical compositions containing them and their use | |
| JP2004517090A5 (en) | ||
| US20220135614A1 (en) | Synthesis of bicycle toxin conjugates, and intermediates thereof | |
| TW200913998A (en) | Heterocycle-aryl compounds for inflammation and immune-related uses | |
| Moynihan et al. | Impurity occurrence and removal in crystalline products from process reactions | |
| JP6644685B2 (en) | Preparation of pomalidomide and improved method for its purification | |
| EP1807421B1 (en) | 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof | |
| JP2011529451A5 (en) | ||
| TW425392B (en) | Oxazolidinonecarboxylic acid derivatives for use as adhesion receptor antagonists preparation process therefor and pharmaceutical composition comprising the same | |
| CN103764648B (en) | Pyrrolidin-3-ylacetic acid derivatives | |
| WO2008003855A2 (en) | Use of 2-benzoyl-imidazopyridines in therapeutics | |
| JP2008222630A (en) | PRODUCTION METHOD OF R-II TYPE CRYSTAL OF 1-beta-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE | |
| JP2005187357A (en) | Method for producing benzothiazolone derivative having selective β2 receptor agonist activity | |
| WO2017025031A1 (en) | Diazaoxa heterocyclic spiro-dione piperazine alkaloid derivative having antiviral activity and preparation method thereof | |
| TW201019951A (en) | Novel semi-synthetic glycopeptides as antibacterial agents | |
| US10961194B2 (en) | Method for purifying ropinirole hydrochloride | |
| TWI230157B (en) | Process for the preparation of 5-hydroxymethyl 2-oxazolidinone and novel intermediate | |
| US20250109126A1 (en) | Dihydro-oxazol derivative compounds | |
| US20110105763A1 (en) | Process for Preparing Valsartan | |
| FR2903108A1 (en) | USE OF IMIDAZO [1,2-A] PYRIDINE-2-CARBOXAMIDE DERIVATIVES IN THERAPEUTICS. | |
| CA2371222C (en) | Functionalised solid support for alpha-oxoaldehyde synthesis | |
| CS243485B2 (en) | Method of benzothienylglycylcephaelosporines production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |